EXHIBIT 10.5
Dated 20 August 0000
XXXX XXXXXXXXXXX, plc
AND
LIGAND PHARMACEUTICALS INCORPORATED
AMENDMENT TO DEVELOPMENT, LICENCE AND SUPPLY AGREEMENT
THIS AMENDMENT AGREEMENT is made on 20 August 1999.
BETWEEN:
(1) ELAN CORPORATION, PLC, a company incorporated in Ireland having its
registered office at Xxxxxxx Xxxxx, Xxxxxxx Xxxxx, Xxxxxx 0, Xxxxxxx
("ELAN") and
(2) LIGAND PHARMACEUTICALS INCORPORATED, a company organized under the laws of
Delaware, with offices at 00000 Xxxxxxx Xxxxxx Xxxxx, Xxx Xxxxx, Xxxxxxxxxx
00000, Xxxxxx Xxxxxx of America ("LIGAND").
RECITALS:
A. ELAN and LIGAND entered into a Development, License and Supply Agreement
dated 9 November, 1998 ("the Agreement").
B. The clinical costs associated with the Agreement have transpired to be
greater than ELAN and LIGAND originally envisaged and accordingly, ELAN and
LIGAND wish to enter into this Amendment Agreement to adjust the license
royalties payable to ELAN under Clause 10.1 of the Agreement, and also the
commitment by LIGAND under Clause 5.5 of the Agreement to undertake
additional clinical expenditure, including Phase III and Phase IV clinical
trials, related to the commercialization of the PRODUCT in the TERRITORY,
to the extent set forth in Clause I hereof.
All capitalized terms used in this Amendment Agreement shall have the same
meanings as are assigned thereto in the Agreement, except where expressly
provided to the contrary in this Amendment Agreement.
NOW IT IS HEREBY AGREED AS FOLLOWS:
1 Amendment to the Agreement:
ELAN and LIGAND hereby agree that the Agreement shall be amended as follows:
1.1 by the deletion of Clause I 0. I of the Agreement and the substitution
therefor of the following:
"10.1 Licence Royalties:
10.1.1 In consideration of the licence of the ELAN PATENTS granted to
LIGAND under this Agreement, LIGAND shall pay to ELAN the
following amounts:-
(1) $5 million in cash or in shares of Common Stock of
LIGAND, par value $.001 per share (the "Common Stock")
(valued at $11.65 per share), at LIGAND's option, upon
the execution of the Agreement by both parties;
(2) $10 million in cash, or at LIGAND's option, in cash
through an increase in the issue amount of the
CONVERTE3LE NOTE, upon the execution of the Agreement
by both parties;
(3) *** in cash or in shares of Common Stock of LIGAND
(valued at a price per share equal to the average of
the CLOSING PRICE of the Common Stock for the 5
consecutive trading days immediately prior to the
required payment date thereof), at LIGAND's option,
upon substantial completion of full original patient
enrolment in the Phase III pivotal efficacy studies
relating to the submission of the NDA for the PRODUCT
in the U.S.A. if, and only if, accomplished-on or prior
to *** .
(4) *** in cash or in shares of Common Stock of LIGAND
(valued at a price per share equal to the average of
the CLOSING PRICE of the Common Stock for the 5
consecutive trading days immediately prior to the
required payment date thereof), at LIGAND's option,
upon submission of the NDA for the PRODUCT in the
U.S.A. provided the exact amount of this payment will
be determined (and become payable) in accordance with
the date upon which the NDA for the PRODUCT is
submitted in the USA, as specified below:
*** upon submission of the NDA for the PRODUCT in the
U.S.A. on or prior to *** ;
*** upon submission of the NDA for the PRODUCT in the
U.S.A. after *** but on or prior to *** ;
*** upon submission of the NDA for the PRODUCT in the
U.S.A. after *** but on or prior to *** ;
*** upon submission of the NDA for the PRODUCT in the
U.S.A. after *** but on or prior to *** ;
--------------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
3
*** upon submission of the NDA for the PRODUCT in the
U.S.A. *** but on or prior to *** ;
*** upon submission of the NDA for the PRODUCT in the
U.S.A. on any date after *** .
(5) *** in cash or in shares of Common Stock of LIGAND (valued
at a price per share equal to the average of the CLOSING
PRICE of the Common Stock for the 5 consecutive trading days
immediately prior to the required payment date thereof), at
LIGAND's option, upon the NDA APPROVAL of the PRODUCT in the
U.S.A.
10.1.2. In the event that LIGAND elects to issue shares of the Common
Stock pursuant to Clause 10.1.1(1), (3), (4) or (5) or the
CONVERTIBLE NOTE pursuant to Clause 10.1.1(2), each such issuance
shall be made pursuant to, and subject to the terms and
conditions set forth in, the PURCHASE AGREEMENT. Nothing in this
Agreement shall relieve LIGAND from its obligations to make the
payments set forth in Clauses 10.1.l.(l), (2), (3), (4) or (5),
in cash, in the event that any of the applicable conditions set
forth in the PURCHASE AGREEMENT are not satisfied or waived on or
prior to the required payment date thereof; provided however,
that in the event that LIGAND elects to issues shares of Common
Stock pursuant to Clause 10.1.1.(1), (3), (4) or (5) and ELAN is
unable to satisfy the conditions to such issuance as set forth in
the PURCHASE AGREEMENT or if such conditions have not been waived
by LIGAND, as the case may be, LIGAND and ELAN shall negotiate in
good faith to agree upon customary terms and conditions which
will enable LIGAND to issue such shares pursuant to a transaction
exempt from the registration requirements of the Securities Act
pursuant to Regulation D thereunder, including the giving by
ELAN, to the extent possible, of representations and warranties
in connection therewith."
1.2 by the deletion of Clause 5.5 of the Agreement and the
substitution therefore of the following:
"5.5 For the *** following submission of the NDA in the USA, LIGAND
shall commit to undertake additional clinical expenditure, ***
*** *** (including FULLY ALLOCATED COST of LIGAND and the sums
paid by LIGAND to ELAN as referred to in Clause 5.4 above). The
objective of the programme so conducted shall be to *** . LIGAND
agrees to carry out and complete the clinical efficacy programme
to a standard and timeframe that LIGAND would otherwise find
acceptable for one of its major branded products. LIGAND shall
keep ELAN informed as to *** *** . LIGAND undertakes that it
shall carry out all *** to prevailing cGCP and CGLP and most
specifically in accordance with FDA standards and guidelines. In
the event that LIGAND does not expend *** during the ***
following submission of the NDA in the USA, then, unless
otherwise agreed in writing between the parties, LIGAND shall pay
any shortfall between the *** and the actual sum expended by
LIGAND to ELAN, provided however, in the event the FDA notifies
ELAN of its refusal to grant the NDA submitted by ELAN and
LIGAND, after discussion with ELAN, determines that it is not
commercially viable for LIGAND to incur any additional
development expenses as provided in Clause 5.4, LIGAND shall have
no further obligation to expend or remit sums under this Clause
5. 5. In such event, ELAN shall have the right to terminate this
Agreement. Thereafter, ELAN shall be entitled to research,
develop and commercialise the PRODUCT in the TERRITORY. In the
event of such termination, all monies paid to ELAN by LIGAND
pursuant to this Agreement shall not be recoverable by LIGAND."
--------------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
4
2 Governing law and jurisdiction:
This Amendment Agreement is construed under and ruled by the laws of
New York. For the purposes of this Amendment Agreement the parties submit
to the non- exclusive jurisdiction of the courts of New York.
IN WITNESS of which the parties have executed this Amendment Agreement.
5
Executed by LIGAND on 20 August, 1999
By: /s/Xxxxx Xxxxxxxx
Name: Xxxxx Xxxxxxxx
Title: President & CEO
Executed by ELAN on 20 August, 1999
By: /s/Xxxxxx Xxxxxxxx
Name: Xxxxxx Xxxxxxxx
Title: Executive Vice President
Corporate Development
6
